Don't mess with the DSMB

New England Journal of Medicine

Volumn 363, Issue 5, 2010, Pages 477-478

  Drazen, Jeffrey M ^c   Wood, Alastair J J ^a,b  

^a Symphony Capital   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; PIOGLITAZONE; ROSIGLITAZONE; SIMVASTATIN; VITAMIN D;

AORTA STENOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DATA AND SAFETY MONITORING BOARD; DIABETES MELLITUS; DRUG SURVEILLANCE PROGRAM; EDITORIAL; HEALTH CARE ORGANIZATION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENAL PROTECTION;

EID: 77955061588     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1007445     Document Type: Editorial

References (6)

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. [Erratum, N Engl J Med 2007;357:100.]
2. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007;357:28-38.
3. Baucus M, Grassley C. Senate Finance Committee report on diabetes drug Avandia. Washington, DC: U.S. Senate Committee on Finance, February 20, 2010.
4. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56.
5. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008;359:1357-66.
6. Califf RM, Harrington RA, Blazing MA. Premature release of data from clinical trials of ezetimibe. N Engl J Med 2009;361:712-7.